派罗欣治疗慢性乙肝18例临床观察  

The Clinical Investigation of 18 Patients with CHB Treated with PEG-INFα-2a

作　　者：曾卫新[1] 谭荣欣[1] 尹燕耀[1] 

机构地区：[1]南昌市第九医院,江西南昌330002

出　　处：《实用临床医学（江西）》2005年第12期36-38,共3页Practical Clinical Medicine

摘　　要：目的:探讨派罗欣治疗慢性乙肝的临床疗效。方法:18例慢性乙肝患者采用派罗欣治疗。肝脏组织损伤程度采用Knodell计分法、血清HBV DNA采用PCR技术及肝功能检测,并对治疗前后的检测结果进行比较。结果:与治疗前相比,治疗后肝组织坏死及炎症程度均明显减轻(P<0.01),治疗后肝组织学活动指数改善率55.6%,门静脉炎症及纤维化程度无明显改善(P>0.05);治疗后血清HBV DNA水平明显下降(P<0.01);治疗后HBeAg血清转换率为50%(9/18)。结论:派罗欣治疗慢性乙肝可明显降低血清HBV DNA的水平,并改善肝组织的炎症及坏死程度,有利于肝功能的稳定。Objective：To investigate the changes of liver function, liver histology and serum HBV- DNA of the patients with CHB treated with PEG-INF-2a. Methods： Eighteen patients were enrolled into this prospective study. Blinded biopsies were scored according to Knodell＇s histology activity index（HAI） ,the serum sample corresponding with liver biopsies were collected,and HBV DNA and e-antigen were measured. Results. Histological assessment revealed a significant improvement in intralobular inflammation and periportal necrosis after treatment（P〈0.01）. 56.6 patients had a reduction of hepatic necro inflammatory HAI in the end. But periportal inflammation and fibrosis failed to show improvement. Serum levels of HBV-DNA decreased significantly after treatment（P〈0. 01）. The clearance rate of HBeAg was 50% after treatment. Conclusion. PEG-INF-2a（40 kDa）can decrease the level of serum HBV-DNA of the patients with CHB,improve the inflammation and necrosis of liver tissue, and maintain the stability of liver function.

关 键 词：肝炎 乙型 慢性 干扰素 组织学 

分 类 号：R512.62[医药卫生—内科学]